The incidence of chronic thromboembolic pulmonary hypertension (CTEPH) after an episode of acute pulmonary embolism (PE) is likely underestimated, a study suggests. This occurs despite the high frequency of symptoms consistent with CTEPH, underscoring that an appropriate diagnostic work-up of CTEPH is rarely undertaken. The study, “CTEPH: a…
Low activity levels in a small RNA molecule called miR126 may be implicated in vascular remodeling — a hallmark feature of pulmonary hypertension (PH) — in the lungs of chronic obstructive pulmonary disease (COPD) patients regardless of whether or not they also have PH, a study reported. This…
Treatment with the approved therapy Uptravi (selexipag) safely reduces disease severity and improves heart and lung health in people with pulmonary hypertension (PH), according to a review study. Researchers recommended that Uptravi be considered for use in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic…
A short treatment with Remodulin (injectable treprostinil) before initiating Orenitram (oral treprostinil) allows pulmonary arterial hypertension (PAH) patients to achieve double the normal doses of the oral therapy without increasing side effects. These are the findings of a preliminary analysis of top-line data from the Phase…
Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million people worldwide living with a rare disease; for many of them, access to diagnosis, care, and treatments can be challenging. Accessing better care depends on…
A ketogenic diet — one that’s low in carbohydrates and higher in fat — given under medical supervision seems to be safe and effective in treating pulmonary hypertension (PH) when it is associated metabolic syndrome, a case report suggests. The report, “Nutritional ketosis to treat pulmonary…
Although pregnancy should be avoided by women with severe pulmonary hypertension (PH), close monitoring by a multidisciplinary team may make it possible in those with moderate PH, a study from China suggests. The study “Long-term outcomes of pregnant women with pulmonary hypertension diagnosed by echocardiography: a…
Intravenous use of Uptravi (selexipag) is safe and well-tolerated by pulmonary arterial hypertension (PAH) patients temporarily unable to take this therapy as an oral tablet, a trial found. Patients reported mild side effects from the switch, with the most frequent being common to both oral and intravenous delivery of Uptravi. The…
The Pulmonary Hypertension Association (PHA) has published a guide that aims to help people recently diagnosed with pulmonary hypertension (PH), as well as their family and caregivers, in better managing the chronic lung disease. The 60-page book, titled “Navigating Pulmonary Hypertension: A Guide for Newly Diagnosed Patients,” covers…
VivaLNK’s wireless device can now be used to capture changes in heart rate and electrical activity in people with pulmonary hypertension (PH) or other disorders during the six-minute walk test (6MWT), a routine exercise endurance test. This wearable electrocardiography (ECG) monitor allows for in-clinic and remote patient…
Remunity, an innovative pump for Remodulin (treprostinil) to treat adults with pulmonary arterial hypertension (PAH), has launched commercial sales, according to the device’s developer, United Therapeutics. The Remunity system allows constant subcutaneous (under-the-skin) delivery of Remodulin (treprostinil). The therapy mimics the effects of prostacyclin, a natural vasodilator…
Australia’s government has taken a step to ensure that Uptravi (selexipag), an oral therapy for pulmonary arterial hypertension (PAH), is available to people affected by the disease. Janssen’s treatment is now included in the country’s Pharmaceutical Benefits Scheme (PBS) listing, meaning it is available to residents in this program…
Get regular updates to your inbox.